Literature DB >> 11156408

Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.

M M Georgescu1, K H Kirsch, P Kaloudis, H Yang, N P Pavletich, H Hanafusa.   

Abstract

PTEN is a tumor suppressor frequently inactivated in brain, prostate, and uterine cancer. It acts as a phosphoinositide phosphatase and consists of an amino-terminal phosphatase domain tightly linked to a COOH-terminal C2 domain involved in lipid membrane-binding. We investigated the functions of the C2 domain and their relevance for tumor growth. To discriminate between PTEN C2 domain ability to recruit or to position the active site to the membrane, we artificially membrane-targeted PTEN by a myristoylation signal. This modification increased wild-type PTEN growth inhibition but did not rescue a C2 mutant defective in lipid-binding, suggesting a model in which PTEN C2 domain positions the active site productively with respect to the membrane-bound phosphoinositide substrate. When tumor-derived mutations in the loops that connect the C2 beta-strands were analyzed, we found that these generally destabilized the protein but had variable effects on the phosphatase activity and tumor growth. The magnitude of these effects was dependent on the presence of the COOH-terminal PEST sequences and on the cell type where the mutant proteins were expressed, suggesting the existence of fluctuating structural defects of the mutant protein. One of the C2 loop mutants induced a total loss of PTEN tumor-suppressor function, most likely by affecting both the membrane binding and the protein stability. These data support a double role for PTEN C2 domain in protein stability and in productive orientation of the catalytic site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156408

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

Review 1.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Membrane-binding and activation mechanism of PTEN.

Authors:  Sudipto Das; Jack E Dixon; Wonhwa Cho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

Review 3.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

4.  PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.

Authors:  Z Meng; L-F Jia; Y-H Gan
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

5.  SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.

Authors:  Yvette Langdon; Panna Tandon; Erika Paden; Jennifer Duddy; Joan M Taylor; Frank L Conlon
Journal:  Development       Date:  2012-01-25       Impact factor: 6.868

6.  Cell cycle arrest and apoptosis by expression of a novel TPIP (TPIP-C2) cDNA encoding a C2-domain in HEK-293 cells.

Authors:  Rasmi Rekha Mishra; Jitendra Kumar Chaudhary; Pramod C Rath
Journal:  Mol Biol Rep       Date:  2012-02-07       Impact factor: 2.316

7.  Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.

Authors:  N R Leslie; D Bennett; A Gray; I Pass; K Hoang-Xuan; C P Downes
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

8.  Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.

Authors:  Joseph J Falke
Journal:  Cellscience       Date:  2007

9.  Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids.

Authors:  George McConnachie; Ian Pass; Steven M Walker; C Peter Downes
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

10.  Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium.

Authors:  Jin Woo Kim; Kyung Hwa Kang; Patrick Burrola; Tak W Mak; Greg Lemke
Journal:  Genes Dev       Date:  2008-11-07       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.